Publication | Open Access

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

Quality Of LifeHigh-risk MelanomaOncologyHealth-related QualityCancer ManagementMelanomaClinical TrialsNordic Phase 3Outcomes ResearchPatient-reported OutcomeMedicineHealth Sciences